Nature Communications

Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial

2026-03-31

Full text

DOI https://doi.org/10.1038/s41467-026-71019-5